Lyell Immunopharma expects 2027 FDA End-of-Phase 1 meeting for LYL273 colorectal cancer trial

• Lyell Immunopharma completed a manufacturing transfer for LYL273, its GCC-targeted CAR T-cell candidate for metastatic colorectal cancer.
• The Phase 1/2 trial continues enrollment to set a recommended Phase 2 dose and refine safety management, using product made at LyFE.
• Earlier results were already described as encouraging clinical activity, without new efficacy updates in this announcement.
• Additional clinical data will be presented in 2027, alongside an End-of-Phase 1 FDA meeting planned for that year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lyell Immunopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609101605PRIMZONEFULLFEED9824900) on September 10, 2026, and is solely responsible for the information contained therein.